Discovery of activation of cancer-fighting T cells by inosine, enabled by Biolog metabolic assay technology

HAYWARD, Calif., Aug. 14, 2020 (GLOBE NEWSWIRE) — A multi-site research team headed by Dr. Ruoning Wang at the Nationwide Children’s Hospital has uncovered a metabolic pathway that can potentially be exploited to enhance the killing of anti-cancer T cells such as CAR-T cells.    Immunotherapies using T cells have been shown to be effective in clinical treatment against B cell leukemias and checkpoint blockade therapies in melanoma, non-small-cell lung cancer, bladder cancer, and others.  However, the success of the T cell therapy is limited to less than one-quarter of cancers.  Hence, many cancer researchers are looking for novel ways to improve T cell based cancer therapies.   
The approach of the research team was to study the metabolic fitness of T cells.  Cancer cells are metabolically strong, and solid tumors create a tumor microenvironment which presents challenges and barriers to block the normal immune response spearheaded by T cells.  Essentially, the cancer cells too often outcompete the immune cells called effector T cells.  Human effector T cells were prepared and tested using Biolog’s Phenotype MicroArray™ set of 367 nutritional carbon sources.  As expected, the effector T cells showed primarily metabolism of sugars, but surprisingly they also showed rather strong metabolism of the nucleoside inosine.  Metabolism of inosine to produce energy was noted in a 2011 paper by Biolog scientists.  More importantly, this new study showed that inosine could restore proliferation of human and mouse effector T cells by relieving starvation after exhaustion of glucose (i.e., blood sugar).  Cancer cells are noted for their ability to consume glucose.  Thus, utilization of inosine provides effector T cells with another nutritional option for surviving in the tumor microenvironment. 
 
Dr. Wang’s team further showed that the ability of the effector T cells to consume inosine required the enzyme purine nucleoside phosphorylase (PNP).  This enzyme converts inosine to hypoxanthine plus ribose-1-phosphate, an important metabolite that can be utilized by cells for growth and energy production.  Some cancer cells also have PNP and can therefore still compete for inosine with the effector T cells.  However for those cancer types with little or no PNP, the effector T cells can outcompete the cancer cells and significantly extend the life of mice with implanted tumors.  Experiments showed that provision of inosine enhances the killing of PNP deficient cancer cells both with CAR-T cells and with T cells provided antibodies against checkpoint blockade inhibitors such as PDL-1.About Biolog, Inc.Biolog is a privately held company based in Hayward, CA, that continues to lead in the development of powerful new cell analysis tools for solving critical problems in biological, pharmaceutical, and biotechnological research and development.  It is the world leader in phenotypic cell profiling.  In addition to the Phenotype MicroArray™ product line, the company has recently introduced a new MitoPlate™ product line that can measure more than 50 properties of human cell mitochondria. These, as well as the Phenotype MicroArray assays, can all be read on Biolog’s versatile OmniLog® instrument.  Product information and details about the MitoPlates can be found at: http://www.biolog.com/products-static/mitochondrial_function_assays.php.  Biolog products are available worldwide, either directly from the company or through its extensive network of international distributors.  Further information can be obtained at Biolog’s website, www.biolog.com.For more information contact:
Andrew Wung
(510) 670-3336
[email protected]

Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow